Antiepileptic Drugs
Combination Therapy and Interactions

This book reviews the use of antiepileptic drugs focusing on the interactions between these drugs, and between antiepileptics and other drugs. These interactions can be beneficial or can cause harm. The aim of this book is to increase awareness of the possible impact of combination pharmacotherapies. Pharmacokinetic and pharmacodynamic interactions are discussed supported by clinical and experimental data. The book consists of five parts covering the general concepts and advantages of combination therapies, the principles of drug interactions, the mechanisms of interactions, drug interactions in specific populations or in patients with co-morbid health conditions, concluding with a look at the future directions for this field of research. The book will be of interest to all who prescribe antiepileptics to epileptic and non-epileptic patients, including epileptologists, neurologists, neuropediatricians, psychiatrists and general practitioners.
Antiepileptic Drugs
Combination Therapy and Interactions

Edited by

Jerzy Majkowski
The Foundation of Epileptology, Warsaw

Blaise F. D. Bourgeois
Harvard Medical School, USA

Philip N. Patsalos
Institute of Neurology, UK

and

Richard H. Mattson
Yale University School of Medicine, USA
Contents

List of contributors ix
Foreword Giuliano Avanzini xiii
Foreword Torbjörn Tomson xv
Acknowledgements xvii

Part I  Introduction 1

1 Combination therapy of diseases: general concepts 3
   Emma Mason and Philip A. Routledge

2 Combination therapy with antiepileptic drugs: potential advantages and problems 16
   Richard H. Mattson

3 Pharmacogenetic aspects 26
   Matthew C. Walker, Michael R. Johnson and Philip N. Patsalos

Part II  Pharmacokinetic interactions 45

4 Pharmacokinetic principles and mechanisms of drug interactions 47
   Philip N. Patsalos

5 Predictability of metabolic antiepileptic drug interactions 57
   Edoardo Spina, Emilio Perucca and Rene Levy

6 Influence of food and drugs on the bioavailability of antiepileptic drugs 93
   Carlos A. Fontes Ribeiro

7 Interactions between antiepileptic drugs 111
   Bernhard Rambeck and Theodor W. May

8 Interactions between antiepileptic and non-antiepileptic drugs 139
   Jerzy Majkowski and Philip N. Patsalos
<table>
<thead>
<tr>
<th>Part III</th>
<th>Pharmacodynamic interactions</th>
<th>179</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Pharmacodynamic principles and mechanisms of drug interactions</td>
<td>181</td>
</tr>
<tr>
<td></td>
<td>Blaise F. D. Bourgeois</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Methods for assessing pharmacodynamic interactions</td>
<td>193</td>
</tr>
<tr>
<td></td>
<td>Blaise F. D. Bourgeois</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Experimental studies of pharmacodynamic interactions</td>
<td>208</td>
</tr>
<tr>
<td></td>
<td>Stanislaw J. Czuczwar</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Clinical studies of pharmacodynamic interactions</td>
<td>228</td>
</tr>
<tr>
<td></td>
<td>John R. Pollard and Jacqueline French</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Clinical studies of pharmacodynamic interactions between antiepileptic drugs and other drugs</td>
<td>241</td>
</tr>
<tr>
<td></td>
<td>Gaetano Zaccara, Andrea Messori and Massimo Cincotta</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Part IV</th>
<th>Drug interactions in specific patient populations and special conditions</th>
<th>255</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>Antiepileptic drug interactions in children</td>
<td>257</td>
</tr>
<tr>
<td></td>
<td>Olivier Dulac, Elizabeth Rey and Catherine Chiron</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Antiepileptic drug interactions in the elderly</td>
<td>273</td>
</tr>
<tr>
<td></td>
<td>Jeannine M. Conway and James C. Cloyd</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Antiepileptic drug interactions in pregnancy</td>
<td>294</td>
</tr>
<tr>
<td></td>
<td>Mark S. Yerby</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Antiepileptic drug interactions in handicapped and mentally retarded patients</td>
<td>325</td>
</tr>
<tr>
<td></td>
<td>Matti Sillanpää</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Antiepileptic drugs and sex steroids</td>
<td>341</td>
</tr>
<tr>
<td></td>
<td>Richard H. Mattson</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Antiepileptic drug interactions in patients requiring psychiatric drug treatment</td>
<td>350</td>
</tr>
<tr>
<td></td>
<td>Michael R. Trimble and Marco Mula</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Antiepileptic drugs in non-epileptic health conditions: possible interactions</td>
<td>369</td>
</tr>
<tr>
<td></td>
<td>Jerzy Majkowski</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Drug monitoring in combination therapy</td>
<td>392</td>
</tr>
<tr>
<td></td>
<td>Walter Fröschner</td>
<td></td>
</tr>
<tr>
<td>vii</td>
<td>Contents</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>----------</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Cognitive side-effects due to antiepileptic drug combinations and interactions 403</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Albert P. Aldenkamp, Mark de Krom, Irene Kotsopoulos and Jan Vermeulen</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Selection of drug combinations in clinical practice: current and future perspectives 421</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jerzy Majkowski</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Future research: an experimental perspective 441</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rob A. Voskuyl, Daniel M. Jonker and Fernando H. Lopes da Silva</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Future research: a clinical prospective 458</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carlos A. Fontes Ribeiro</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Index 475</td>
<td></td>
</tr>
</tbody>
</table>
List of contributors

Professor Albert P. Aldencamp  
Department of Neurology, University  
Hospital of Maastricht, PO Box 21, NL 2100  
AB, Heeze, The Netherlands

Professor Blaise F. D. Bourgeois  
Children’s Hospital – HU2, Harvard Medical  
School, 300 Longwood Avenue, Boston,  
MA 02115, USA

Dr Catherine Chiron  
Hospital Necker-Enfants Malades, 149 Rue  
de Sevres, Paris 75015, France

Dr Massimo Cincotta  
Unit of Neurology, Santa Maria Nuova  
Hospital, Florence, Italy

Dr James C. Cloyd  
College of Pharmacy, University of  
Minnesota, Room 7101, Weaver Densford  
Hall, 308 Harvard St SE, Minneapolis,  
MN 55455 0353, USA

Dr Jeanne M. Conway  
College of Pharmacy, University of  
Minnesota, 7-170 WDH, 308 Harvard St SE,  
Minneapolis, MN 55455, USA

Professor Stanislaw J. Czuczwar  
Department of Pathophysiology, Medical  
Academy, Jacezewskiego 8, 820-090 Lublin,  
Poland

Dr Mark de Krom  
Department of Neurology, University  
Hospital of Maastricht, PO Box 21, NL 2100  
AB, Heeze, The Netherlands

Professor Olivier Dulac  
Hospital Necker-Enfants Malades, 149 Rue  
de Sevres, Paris 75015, France

Professor Carlos A. Fontes Ribeiro  
Department of Pharmacology,  
Faculty of Medicine, 3000 Coimbra,  
Portugal

Professor Jacqueline French  
Department of Neurology, 3 West Gates,  
Hospital of the University of Pennsylvania,  
3400 Spruce St, PA 19104, USA

Professor Walter Fröscher  
Department of Neurology and Epileptology,  
Die Weissenau (Department of Psychiatry I),  
University of Ulm, D-88214 Ravensburg,  
Germany

Dr Michael R. Johnson  
Division of Neurosciences and Psychological  
Medicine, Imperial College London,  
Charing Cross Hospital, London,  
W6 8RP, UK

Dr Daniel M. Jonker  
Epilepsy Institute of the Netherlands (SEIN),  
Achterweg 5, NL 21 03 SW,  
Heemstede, The Netherlands
List of contributors

Dr Irene Kotsopoulos
Department of Neurology, University Hospital of Maastricht, PO Box 21, NL 2100 AB, Heeze, The Netherlands

Professor Rene Levy
Department of Pharmaceutics, School of Pharmacy, University of Washington, Health Sciences Center H-Wing, Suite 272, Seattle, WA 98195, USA

Professor Fernando H. Lopes da Silva
Epilepsy Institute of the Netherlands (SEIN), Achterweg 5, NL 21 03 SW, Heemstede, The Netherlands

Professor Jerzy Majkowski
Diagnostic and Therapeutic Center for Epilepsy, Foundation of Epileptology, ul Wiertnicza 122, 02-952 Warsaw, Poland

Dr Emma Mason
Department of Pharmacology, Therapeutics and Toxicology, Wales College of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

Professor Richard H. Mattson
Department of Neurology, Yale University 701 LC1, 33 Cedar Street, New Haven, CT 06510, USA

Dr Theodor W. May
Biochemisches Labor der Gesellschaft für Epilepsieforschung, Maraweg 13, D-33617 Bielefeld, Germany

Dr Andrea Messori
Unit of Pharmacy, Careggi Hospital, Florence, Italy

Dr Marco Mula
Amadeo Avogadro University, C.so Mazzini, 18 28100 Novara, Italy

Professor Philip N. Patsalos
Pharmacology and Therapeutic Unit, Department of Clinical and Experimental Epilepsy, Institute of Neurology, Queen Square, London, WC1N 3BG; The National Society for Epilepsy, Chalfont St Peter, UK

Professor Emilio Perucca
Clinical Pharmacology Unit, University of Pavia, Piazza Botta 10, I 27100 Pavia, Italy

Dr John R. Pollard
Department of Neurology, 3 West Gates, Hospital of the University of Pennsylvania, 3400 Spruce St, PA 19104, USA

Dr Bernhard Rambeck
Biochemisches Labor der Gesellschaft für Epilepsieforschung, Maraweg 13, D-33617 Bielefeld, Germany

Dr Elizabeth Rey
Hôpital Saint Vincent de Paul, Paris, France

Professor Philip A. Routledge
Department of Pharmacology, Therapeutics and Toxicology, Wales College of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

Professor Matti Sillanpää
Department of Public Health, 20014 Turku University, Turku, Finland

Professor Edoardo Spina
Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Policlinico Universitario, Via Consolare Valeria, 98125 Messina, Italy

Professor Michael R. Trimble
The National Hospital for Neurology and Neurosurgery, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
xi List of contributors

Dr Jan Vermeulen
Epilepsy centre SEIN, Heemstede,
The Netherlands

Dr Rob A. Voskuyl
LACDR, Division of Pharmacology,
Gorlaeus Laboratories, Postbus 9502,
2300 RA, Leiden, The Netherlands

Dr Matthew C. Walker
Pharmacology and Therapeutic Unit,
Department of Clinical and Experimental
Epilepsy, Institute of Neurology,
Queen Square, London, WC1N 3BG, UK

Dr Mark S. Yerby
North Pacific Epilepsy Research, 2455 NW
Marshall St, Ste 14, Portland, OR 97201,
USA

Dr Gaetano Zaccara
Department of Neurology, Ospedale S.M.
Nuova, Piazza S.M. Nuova 1, 50124
Florence, Italy
Foreword

It is my special pleasure to introduce this book about the principles on which to base combination antiepileptic drug (AED) therapy and its related problems.

As reviewed in the excellent opening chapter by Mason and Routledge, therapeutic strategies involving the combination of different drugs are currently used to treat hypertension, infectious diseases and cancer in an attempt to enhance efficacy, reduce unwanted side effects and decrease the probability of developing resistance. However, their disadvantages may exceed their benefits. First of all, drug toxicity may actually be increased by combination therapy as a result of negative pharmacodynamic interactions and the increased probability of idiosyncratic reactions. Secondly, the management of combination therapy is complicated by pharmacokinetic interactions. Thirdly, the risks of non-compliance and medication error are significantly greater with a multiple drug regimen.

How these general concepts apply to pharmacological antiepileptic therapy is dealt with by the most authoritative specialists in the first three parts of the book, which give considerable space to pharmacokinetic and pharmacodynamic interactions, while the fourth part develops these questions further with special regard to the patients’ age, associated health problem (neurological or general), and sexual life (contraception, pregnancy, etc.). The reader is thus guided in understanding the rationale for combining AEDs, and made aware of the caveats that need to be taken into account.

In an ideal situation, we should consider AED combinations in such a way as to ensure that each pharmacological ingredient targets a specific epileptogenic mechanism. Unfortunately, our current understanding of the basic mechanisms of epileptogenesis and drug activity is still too limited to make such rational polypharmacy feasible. However, the favourable effects of some combinations based on traditional or newly developed AEDs (or both) is documented in the literature and here critically reviewed. This information is relevant and important when choosing the drug combinations to be prescribed to patients failing to respond to single drug regimens on the basis of exploiting the potential synergies of different drugs.

It is worth noting that the availability of newly developed AEDs has made multiple drug regimens increasingly frequent in clinical practice because, until the
efficacy and tolerability of a given new drug are fully understood it would be inappropriate (and in many instances illegal) to use it as a first choice monotherapy. A good knowledge of the advances and drawbacks of combination therapy is essential for the everyday use of new AEDs.

Appropriate attention is given to the pharmacogenetic aspects underlying the variables that may influence AED responses and interaction profiles, such as metabolism, pharmacokinetics and pharmacodynamics, and there is a critical discussion of the usefulness and pitfalls of genetic screening. Pharmacogenetics and pharmacogenomics are currently seen as speculative perspectives, but it is worth bearing in mind that it is already possible to characterize individuals on the basis of the polymorphisms of genes encoding drug metabolic enzymes, even though the relevance of this approach to the clinical use of combination therapy has not yet been assessed.

This book will stimulate new thoughts and ideas, and I am sure that all of its readers will learn something even about what at first glance may seem familiar subjects. For instance, although I was of course aware that most drug formulations contain multiple ingredients, it had not occurred to me that this makes the very concept of monotherapy rather relative as the active principle may make up as little as 8% of a tablet's weight, with the rest consisting of coating and binding agents, fillers, dyes, preservatives, and solubilising and disintegrating ingredients which, however rarely, may give rise to dose-related or idiosyncratic reactions in susceptible subjects.

In summary, this book will provide readers an updated account of the state of the art and an appraisal of the exciting perspectives of an important aspect of pharmacological antiepileptic therapy. The editors (Jerzy Majkowski, Blaise Bourgeois, Philip Patsalos and Richard Mattson) wrote some of the critical chapters themselves, but also gathered a highly authoritative group of other scientists in order to cover the field comprehensively. In thanking them for this, I wish the book the success it deserves.

Giuliano Avanzini
President of the International League Against Epilepsy
Foreword

Drug interactions may be regarded as a stimulating challenge by the pharmacologist but by the physician responsible for management of the patient, interactions are often considered cumbersome and a vexing factor complicating treatment. Drug interactions are particularly common in the treatment of patients with epilepsy. Although monotherapy has been the favoured treatment strategy for the last 25 years or so, up to 50% may not achieve satisfactory seizure control while on the first drug they have been prescribed. A high proportion of these patients will eventually end up taking a combination of different antiepileptic drugs. Until now, the selection of drug combinations has more often been the result of chance or the physician's individual preferences rather than being rational or evidence-based. Given the long duration of epilepsy treatment, most patients will frequently be prescribed drugs for other conditions too. Conventional antiepileptic drugs have been among the most prone to pharmacokinetic interactions, and pharmacodynamic interactions occur whenever two drugs are used together. For all these reasons, the topic of combination therapy and drug interactions is of great importance and up-to-date knowledge is an essential basis for a rational approach to the pharmacological treatment of people with epilepsy.

The editors of the current book on Antiepileptic drugs: combination therapy and interactions have managed to gather an international group of experts to cover these and related issues in a comprehensive volume. The reader is provided the relevant general background, along with in-depth coverage of pharmacokinetic and pharmacodynamic interactions as well as interactions in specific patient populations. It is made clear that while pharmacokinetic interactions in most cases are negative, recent advances in our understanding of drug metabolism enable us to predict and avoid adverse interactions. Drug level monitoring can help us manage those interactions that cannot be avoided. Pharmacodynamic interactions are not always adverse. Some are advantageous, improving the therapeutic index, and could be exploited to the benefit of our patients. This volume, which should be of interest to all physicians engaged in the treatment of patients with epilepsy, shows how far we have advanced from the level where interactions could be regarded as just an
unwieldy factor complicating pharmacotherapy. Instead, the data provided will hopefully serve as a platform for more rational and effective therapeutic strategies in the future for epilepsy patients in need of combination therapy.

Torbjörn Tomson
Chairman, Commission on Therapeutic Strategies,
International League Against Epilepsy
Acknowledgements

This book has arisen as a result of the activities of the International League Against Epilepsy’s (ILAE) Sub-commission of Polytherapy and Drug Interactions of the Commission on Therapeutic Strategies. Under the auspices of the Sub-commission, three international pre-congress symposia/satellite symposia were organised during the 1st European Congress of Epileptology, Oporto, Portugal, 1994; the 3rd European Congress of Epileptology, Warsaw, Poland, 1998; and the XIV Conference on Epilepsy, Warsaw, Poland, 2000. These symposia brought together internationally recognised experts in the field of antiepileptic drug interactions and it is these experts that have contributed the chapters that constitute this book. The activities of the Sub-commission of Polytherapy and Drug Interactions and thus this book would not have been possible without the generous financial support of the ILAE, Polish Society of Epileptology, Abbott, Aventis, GlaxoSmithKline, Hoechst Marion Roussel, Novartis, Ortho (Johnson and Johnson) and Pfizer.

J. Majkowski, B.F.D. Bourgeois, P.N. Patsalos and R.H. Mattson